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Objectives: Rheumatoid arthritis (RA) is characterized by defective bone repair and exces-
sive destruction and ankylosing spondylitis (AS) by increased ectopic bone formation with
syndesmophytes. Since TNF-α and IL-17A are involved in both diseases, this study investi-
gated their effects on the osteogenic differentiation of isolated human bone marrow-derived
mesenchymal stem cells (hMSCs).
Methods: Differentiation of hMSCs into osteoblasts was induced in the presence or
absence of IL-17A and/or TNF-α. Matrix mineralization (MM) was evaluated by alizarin
red staining and alkaline phosphatase (ALP) activity. mRNA expression was measured by
qRT-PCR for bone morphogenetic protein (BMP)-2 and Runx2, genes associated with osteo-
genesis, DKK-1, a negative regulator of osteogenesis, Schnurri-3 and receptor activator of
nuclear factor kappa B ligand (RANKL), associated with the cross talk with osteoclasts,
and TNF-α receptor type I and TNF-α receptor type II (TNFRII).
Results:TNF-α alone increased both MM and ALP activity. IL-17A alone increased ALP but
not MM.Their combination was more potent.TNF-α alone increased BMP2 mRNA expres-
sion at 6 and 12 h. These levels decreased in combination with IL-17A at 6 h only. DKK-1
mRNA expression was inhibited byTNF-α and IL-17A either alone or combined. Supporting
an imbalance toward osteoblastogenesis, RANKL expression was inhibited by TNF-α and
IL-17A. However, TNF-α but not IL-17 alone decreased Runx2 mRNA expression at 6 h. In
parallel, TNF-α but not IL-17 alone increased Schnurri-3 expression with a synergistic effect
with their combination. This may be related to an increase of TNFRII overexpression.
Conclusion: IL-17 increased the effects ofTNF-α on bone matrix formation by hMSCs. How-
ever, IL-17 decreased theTNF-α-induced BMP2 inhibition. Synergistic interactions between
TNF-α and IL-17 were seen for RANKL inhibition and Schnurri-3 induction. Such increase of
Schnurri-3 may in turn activate osteoclasts leading to bone destruction as in RA. Conversely,
in the absence of osteoclasts, this could promote ectopic bone formation as in AS.
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INTRODUCTION
Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that
contributes to the pathogenesis of several inflammatory diseases
(1, 2). In rheumatoid arthritis (RA), there is excessive bone
destruction and defective bone repair leading to massive joint
damage, while in ankylosing spondylitis (AS) there is excessive but
ectopic ossification leading to syndesmophytes combined with sys-
temic bone loss (1,3–5). Moreover, increased levels of IL-17 in both
diseases have suggested its contribution to these bone defects (4).
Furthermore, IL-17A is considered as a new target for treatment of
both RA and AS, as previously shown for TNF-α inhibition (6–11).
Moreover, we have previously found that addition of inhibitors of
Abbreviations: AS, ankylosing spondylitis; BMP2, bone morphogenetic protein
2; DKK-1, dickkopf 1; MSC, mesenchymal stem cell; RA, rheumatoid arthritis;
RANKL, receptor activator of nuclear factor kappa B ligand; Runx2, runt-related
transcription factor-2; Shn3, Schnurri-3.
IL-17A and TNF-α alone or even better in combination, decreases
bone destruction in an ex vivo model of RA (12).
The mechanisms used by IL-17A to promote bone loss include
activation of osteoclastogenesis, which occurs both directly and
also through expression of receptor activator of nuclear fac-
tor kappa B ligand (RANKL) and M-CSF by stromal cells (4,
13). Moreover, IL-17A can induce target cells to produce pro-
inflammatory cytokines such as IL-6, IL-1, CXCL8, TNF, and
matrix metalloproteinases (2, 14–17). On the other hand, TNF-α
inhibits osteoblastogenesis through increased expression of Dick-
kopf 1 (DKK-1) (18, 19) and induces bone loss by degradation of
bone morphogenetic protein (BMP)-2 signaling via Smad ubiqui-
tin regulatory factor (Smurf)1 and NF-kB (20–22). In contrast
to their classical effects on bone loss, some studies have indi-
cated that IL-17A and TNF-α possibly could increase osteogenesis
(23–30). IL-17A can induce proliferation and differentiation of
human mesenchymal stem cells (hMSCs) in a manner dependent
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on the generation of reactive oxygen species (ROS) (31). Moreover,
IL-17A can significantly increased leptin production that inhibits
adipogenesis and promotes osteogenesis on human bone marrow-
derived mesenchymal stem cells (hMSCs) via JAK/STAT signaling
(23). TNF-α can promote osteogenic differentiation through trig-
gering NF-kB and enhancing the expression of BMP2 and RUNX2
(24, 25, 28).
Due to these conflicting results, our objective was to examine
whether IL-17A alone and/or TNF-α, positively or negatively mod-
ulate osteogenic differentiation in hMSCs. To study these aspects,
we focused on key genes involved in bone turnover: BMP2, Runx2,
DKK-1, RANKL, and Schnurri-3, a gene recently associated with
bone resorption in mice (32–34), but with a paucity of data on its
role in the human context.
MATERIALS AND METHODS
CELL CULTURE, OSTEOGENIC INDUCTION, AND EXPERIMENTAL DESIGN
hMSCs were provided by the cell therapy department. They
were obtained from residues of quality controls of bone mar-
row for transplantation harvested from adult donors after signing
an informed consent. A fibroblast colony-forming unit (CFU-
F) was used to optimize culture and expansion of hMSCs.
Cells were cultured at 37°C in α-MEM (Lonza, Verviers, Bel-
gium) supplemented with 10% fetal bovine serum (FBS-Hyclone,
Thermo scientific, Saint Aubin, France), 2 mM l-glutamine,
100 U/ml penicillin, streptomycin. Cells were used between pas-
sage 3 and 6 at which cells were >99% stained negative for
CD34 and CD45 and positive for CD73 and CD90 (anti-
bodies obtained from PharMingen). For osteogenic differen-
tiation, hMSCs were plated at a density of 5× 103 cells/cm2
and cultured in stem Xvivo Osteogenic/adipogenic base Medium
(R&D systems, Lille, France), supplemented with 100 nM dex-
amethasone (Sigma, saint Quentin-Fallavier, France), 10 mM β-
glycerophosphate (Sigma), and 50µM ascorbic acid (Sigma).
hMSCs were differentiated for 21 days in the absence or presence of
1 ng/ml TNF-α (R&D systems, Lille, France) and/or 50 ng/ml IL-
17A (R&D systems) (23, 24, 31). Half of the medium was changed
every 3 days.
MINERALIZATION ASSAY
Cells were washed twice with PBS, fixed with 70% cooled ethanol
for 1 h, and then washed with water. Cells were stained for 20 min
at ambient temperature with alizarin red (pH: 4.2, 40 min, Sigma)
and examined under light microscope. The red color obtained
referred to calcium deposit.
ALKALINE PHOSPHATASE ASSAY
hMSCs seeded in 12-well plates were lysed with the assay buffer
(Abcam, Paris, France). The protein contents in the lysates were
determined using the Bradford protein assay (Sigma). Ten micro-
liters from the remaining lysate was mixed with 20µl of MUP, used
as a substrate (Abcam) in a 96-well plate, and incubated at room
temperature for 30 min. Fluorescence intensity was measured
at extension/emission of 360/440 nm. The alkaline phosphatase
(ALP) activity was normalized to protein content and expressed
as unit per microgram protein.
QUANTITATIVE RT-PCR ANALYSIS
RNA was purified using RNeasy kits (Qiagen, Les Ulis, France).
The concentration of RNA was quantified by spectrophotome-
try (SmartSpec™ 3000, Biorad, Hercules, CA, USA). Five hun-
dred nanograms of total RNA was reverse transcribed with the
Quanti Tec Reverse Transcription (Qiagen Kit) into cDNA. PCR
amplification was performed on a Light Cycler (Roche Diagnos-
tics, Switzerland) using Fast-Start™ DNA Master SYBR Green I
real-time PCR kit (Roche Molecular Biochemicals, Switzerland).
The expression of the genes was normalized to the expression
of human cyclophilin B (CPB) (Qiagen; 5′tgtggtgtttggcaaagttc3′;
3′gtttatcccggctgtctgtc5′). The list of primers (Qiagen) is as fol-
lows: BMP2 (5′ccaccatgaagaatctttgga3′; 3′gagttggctgttgcaggttt5′),
RUNX2 (5′gtggacgaggcaagagttt3′; 3′tggggtctgtaatctgactc5′), DKK-
1 (5′ccttggatgggtattccaga3′; 3′tccatgagagccttttctcc5′), RANKL
(5′accagcatcaaaatcccagg3′; 3′ccccaaagtatgttgcatcc5′),Shn 3 (5′ccctg
agccataaccctgaa 3′; 3′gtaggacttggcgttggtgt 5′), TNF-α receptor type
II (TNFRII) (5′ ggtctccttgctgctgtttc3′; 3′ccggagattctcaaatccaa5′),
and TNF-α receptor type I (TNFRI) (5′ accaagtgccacaaaggaac 3′;
3′ctgcaattgaagcactggaa 5′).
STATISTICAL ANALYSIS
Analysis was performed using a Wilcoxon test from Graphpad
Prism. p-Values were determined for every analysis. p-Values
<0.05 were considered significant.
RESULTS
SYNERGISTIC EFFECTS OF IL-17A AND TNF-α ON EXTRACELLULAR
MATRIX MINERALIZATION
A key characteristic of MSCs is their ability to differentiate into
cells of different tissue lineages. Mineralization of the extracellular
matrix is a marker of hMSCs differentiation into osteoblasts. To
evaluate the effects of IL-17A and/or TNF-α on MM, hMSCs were
cultured for 21 days in a medium supplemented with osteogenic
factors with and without cytokines. Alizarin red staining was used
to visualize mineralization. As shown in Figure 1A, column 2, cul-
ture of MSC with osteogenic factors alone induced a weak MM,
which appeared at day 17 and reached its maximum level at day
21. Addition of IL-17A alone did not modify this mineralization
(Figure 1A, column 3; Figure 1B). Addition of TNF-α enhanced
this mineralization at day 17 (Figure 1A, column 4; Figure 1B,
*p< 0.05), which was further enhanced in the presence of the two
cytokines (Figure 1A, column 5; Figure 1B, **p< 0.005). At day
21, maximum levels were observed in each condition except in
the negative control. Thus, these results show that TNF-α but not
IL-17A alone enhanced bone mineralization, which was further
potentiated but without acceleration by IL-17A.
SYNERGISTIC EFFECTS OF IL-17A AND TNF-α ON ALKALINE
PHOSPHATASE ACTIVITY
Since TNF-α and IL-17A increased mineralization of the extracel-
lular matrix, we next investigated their effects on ALP, an enzyme,
which is essential for bone mineralization. ALP activity was mea-
sured at days 3, 5, 7, and 14 (Figure 2). At day 3, no difference in
the presence or absence of cytokine was detected. Increased levels
of ALP activity were detected at day 5 when the two cytokines
were combined (4.4× 103 U/ml at day 3 vs. 7.4× 103 U/ml at
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FIGURE 1 | Effects of IL-17A and/orTNF-α on extracellular matrix
mineralization are shown. hMSCs were plated at a density 5×103 cell/cm2
and cultured for 21 days (A) in the absence (column 1) or presence (column 2)
of osteogenic factors, 1 ng/ml TNF-α (column 3) or 50 ng/ml IL-17A (column 4),
or both (column 5) were added or not to cultures. Plates were then stained
with alizarin red, which colors calcium deposits in the extracellular matrix.
(B) Results of day 17 were analyzed using the Wilcoxon test. *p<0.05;
**p< 0.005 vs. induction medium alone.
FIGURE 2 | Effects of IL-17A and/orTNF-α on alkaline phosphatase
activity are shown. hMSCs were plated at a density of 5×103 cell/cm2,
cells were cultured in osteogenic medium for 14 days, in the absence (0) or
presence of TNF-α 1 ng/ml and/or IL-17A 50 ng/ml. ALP activity was
measured by fluorometry. Results were analyzed using the Wilcoxon test.
*p<0.05; **p<0.005 vs. induction medium alone.
day 5, *p< 0.05) or at day 7 in the presence of each cytokine
alone (Figure 2). Moreover, the combination of the two cytokines
resulted in a further increase of ALP activity, the maximum level
being achieved at day 7 (1.8× 103 U/ml without cytokine vs.
1.3× 104 U/ml with both cytokines, **p< 0.005). Day 14 shows
almost the same results as day 7.
Therefore, these results support those of the alizarin red
staining, by showing that the combined action of IL-17A and
TNF-α resulted in synergistically increasing and accelerating
osteoblast differentiation from hMSCs. However, ALP activity
appeared more sensitive to the effects of IL-17A alone.
TNF-α BUT NOT IL-17A ALONE INCREASES THE EXPRESSION LEVELS OF
BMP2 mRNA
To better understand the effects of IL-17A and TNF-α on the dif-
ferentiation of hMSCs, mRNA expression levels of BMP2 were
measured at 6, 12, 24, and 72 h. BMP2 plays an important role
in the development of bone and cartilage and induces osteoblast
differentiation in a variety of cell types (35). BMP2 mRNA expres-
sion was increased at 6 h with TNF-α alone (16-fold with TNF-α
as compared with control without cytokine, **p< 0.05), with a
kinetic curve demonstrating a decrease upon time (Figure 3). IL-
17A alone did not change BMP2 mRNA expression levels. The
combination of the two cytokines resulted in a significant decrease
of BMP2 mRNA expression as compared with the effects of TNF-α
alone at 6 h (16-fold with TNF-α vs. 9-fold with TNF-α+ IL-17A,
#p< 0.05). This inhibitory effect was not seen at 12 h (5.0-fold
TNF-α vs. 5.4-fold IL-17A+TNF-α, NS). Overall, the combina-
tion of these two cytokines resulted in a significant increase of
BMP2 mRNA expression as compared with controls (ninefold
with TNF-α+ IL-17A vs. control, *p< 0.05, at 6 h, and 5.4-fold
at 12 h). Therefore, these results showed that TNF-α increased the
expression of BMP2 mRNA levels, an effect, which was inhibited
by IL-17A.
IL-17A AND TNF-α INCREASE THE EXPRESSION LEVEL OF Shn3 mRNA
BUT NOT THOSE OF Runx2
Schnurri-3 (Shn3) is a zinc finger protein, which plays a key regu-
latory role in skeletal remodeling in mouse (36). In hMSCs, Shn3-
mRNA expression levels increased significantly only at early 6 h
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in the presence of TNF-α alone (twofold with TNF-α, *p< 0.05)
with a kinetic curve demonstrating a decrease upon time. IL-17A
alone did not change Shn3-mRNA expression levels (Figure 4A).
The combination of the two cytokines resulted in a significant
increase of Shn3-mRNA expression as compared with the effects
of TNF-α alone at 6 h (fivefold with IL-17A+TNF-α vs. twofold
with TNF-α, ##p< 0.005). No significant change of Shn3-mRNA
expression levels was observed in the presence of either one or two
cytokines between 12 and 24 h.
Runx2 is a key transcription factor that has been associated with
osteogenesis (37). However, its mRNA expression levels showed no
increase but rather unexpectedly a significant decrease at 6 h in the
FIGURE 3 | Effects of IL-17A andTNF-α on BMP2 are shown. hMSCs
were cultured in osteogenic medium in the presence or absence of TNF-α
1 ng/ml and/or IL-17A 50 ng/ml. Osteogenic gene expression of BMP2 was
measured by qRT-PCR at early time points of (6, 12, 24, and 72 h). Results
were analyzed using the Wilcoxon test. *p<0.05; **p<0.005 vs. induction
medium alone (0), #p<0.05 TNF-α alone vs. IL-17A+TNF-α.
presence of TNF-α alone or combined to IL-17A as compared with
control (0.5-fold with TNF-α or IL-17A+, TNF-α *P< 0.05). No
significant change of Runx2 mRNA expression levels was observed
in the presence of either one or two cytokines between 12 and 72 h
(Figure 4B).
Therefore, TNF-α alone and even more in combination with IL-
17A increased Shn3-mRNA levels and decreased those of RUNX2
at early time points, while IL-17A alone showed no effects.
IL-17A AND TNF-α DECREASE RANKL AND DKK-1 mRNA EXPRESSION
LEVELS
The RANKL produced by osteoblasts plays a key role in osteoclast
differentiation and activation (38). RANKL mRNA expression lev-
els without cytokines remained stable over time, i.e., from 6 to
72 h (Figure 5A). In contrast, RANKL mRNA levels were sig-
nificantly reduced as early as 6 h, when either IL-17A or TNF-α
added alone (0.6-fold with TNF-α, 0.8-fold with IL-17A vs. 1-
fold without cytokine, *p< 0.05). The combined action of the two
cytokines resulted in a more profound decrease of RANKL mRNA
levels (0.1-fold with IL-17A combined to TNF-α vs. 1-fold with-
out cytokine, **p< 0.005). Moreover, this decrease was sustained
upon time, since it was still observed at 24 h (0.35-fold with TNF-α
combined to IL-17A vs. 1-fold without cytokine, *p< 0.05). This
result shows that these two cytokines might enhance osteogenesis
by reducing RANKL expression.
Among the several molecules that negatively regulate Wnt sig-
naling, DKK-1 prevents the activation of the Wnt signaling path-
way (39). Upon differentiation of MSC into osteoblasts, DKK-1
mRNA expression levels without cytokines remained stable over
time, i.e., from 12 to 72 h. In contrast, DKK-1 mRNA levels were
significantly reduced at 72 h, when either IL-17A or TNF-α or
both were added (0.3-fold with TNF-α, IL-17A, alone or com-
bined vs. 1.6-fold without cytokine, *p< 0.05) (Figure 5B). This
suggests that these two cytokines might enhance osteogenesis by
overcoming the negative modulation mediated by DKK-1.
Therefore, these results show a combined action of TNF-α and
IL-17A on hMSCs increased osteogenesis through an inhibition of
DKK-1 and RANKL gene expression.
FIGURE 4 | Effects of Il-17A andTNF-α on Schnurri-3 and Runx2 are shown. hMSCs were cultured in osteogenic medium in the presence or absence of
TNF-α 1 ng/ml and/or IL-17A 50 ng/ml. Osteogenic gene expression Shn3 (A) and Runx2 (B) were measured by qRT-PCR at early time points of 6, 12, 24, and
72 h. Results were analyzed using the Wilcoxon test. *p<0.05; **p<0.005 vs. induction medium alone (0), #p<0.05 TNF-α alone vs. IL-17A+TNF-α.
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FIGURE 5 | Effects of Il-17A andTNF-α on RANKL and DKK-1 expression are shown. hMSCs were cultured in osteogenic medium in the presence or
absence of TNF-α 1 ng/ml and/or IL-17A 50 ng/ml. Osteogenic gene expression RANKL (A) and DKK-1 (B) were measured by qRT-PCR at early time points of 6,
12, and 24 h. Results were analyzed using the Wilcoxon test. *p<0.05; **p< 0.005 vs. induction medium alone (0), #p<0.05 TNF-α alone vs. IL-17A+TNF-α.
COMBINATION OF IL-17A AND TNF-α INCREASE TNFRII BUT NOT TNFRI
EXPRESSION
TNF-α receptor type I and TNFRII play an important role in cell
proliferation, survival, and death (40, 41). Since IL-17 increased
the effects of TNF-α in hMSCs, we looked at a possible effect
on TNF-R expression. Addition of IL-17A and TNF-α alone or
in combination had no effect on TNFRI mRNA expression levels
(Figure 6). On the other hand, IL-17A and TNF-α alone had a very
modest effect on TNFRII mRNA expression levels, but the com-
bination induced a clear increase (2.0-fold with IL-17A+TNFα
vs. 1-fold without cytokine at 12 h (*p< 0.005). Therefore, these
results show that the combined action of TNF-α and IL-17A on
hMSCs may result from TNFRII but not TNFRI overexpression.
DISCUSSION
The goal of this study was to evaluate the effects of cytokines on the
differentiation of human MSCs into bone forming cells, focusing
on TNFα classical target for treatment and on IL-17, an emerging
one, these two cytokines being known to interact. The first conclu-
sion is the effect of TNF-α to promote osteogenic differentiation
of hMSCs by increased deposition of calcium into the extracel-
lular matrix, enhanced ALP activity, enhanced expression BMP2
mRNA levels, and decreased expression of RANKL and DKK-1
mRNA levels with an increase of Schnurri-3. As it is often the case,
the effects of IL-17A alone were absent or limited in similar assays.
The combination of TNF and IL-17 showed complex interactions
with a net effect on enhanced matrix formation, ALP activity, and
Schnurri-3 expression with reduced RANKL expression. A key
surprising effect was the inhibition of the TNF-enhanced BMP2
expression when IL-17 was added.
Previous studies in human and murine systems have already
shown an effect of IL-17A or TNF-α used alone on osteogenic
induction (23–29, 31, 42). However, the classical view describes
TNFα as an inhibitor of bone formation, more particularly with
reference to RA. Among those studies, TNF-α has been reported
to activate through TNF receptor-associated factor-2, a cascade
of biochemical events involving NF-κB, AP-1, and MAPKs, lead-
ing to the activation of osteoclastic resorption and inhibition of
FIGURE 6 | Effects of Il-17A andTNF-α onTNFRI andTNFRII expression
are shown. hMSCs were cultured in osteogenic medium in the presence or
absence of TNF-α 1 ng/ml and/or IL-17A 50 ng/ml. Gene expression of TNFRI
and TNFRII were measured by qRT-PCR at 12 h. Results were analyzed
using the Wilcoxon test. *p<0.005 vs. induction medium alone (0).
osteoblast proliferation and matrix synthesis (43–45). Like TNF-α,
IL-17A also activates NF-κB and AP-1 but through TRAF protein
(46, 47). IL-17A inhibitory effect on matrix production in chon-
drocytes and osteoblasts leads to joint damage. It activates the
production and function of MMPs, and a combination of IL-17A
to TNF leads to irreversible cartilage damage in a murine model
(3). IL-17A seems to increase ALP activity during osteogenesis
and this is in harmony with two previous studies in the human
system (23, 31).
While TNF-α was shown to increase BMP2 expression in dif-
ferent cell types like chondrocytes, endothelial cells, and dental
pulp cells (48–50), little is known about the effects of TNF-α
on BMP2 expression in hMSCs during the process of osteogenic
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differentiation. Here, TNF-α significantly increased BMP2 mRNA
expression in hMSCs within 24 h of treatment (Figure 3) suggest-
ing that TNF-α alone induces osteogenesis by increasing BMP2
expression. Much less is known on the effects of IL-17. IL-17A
alone showed no effect. Instead of the expected potentiation with
the combination with TNF, a reduction was observed at least at
early time points.
Another factor involved in the regulation of osteogenesis is
DKK-1, a major inhibitor of the Wnt signaling pathway (39).
DKK-1 promotes internalization of the receptor complex and
dampens the Wnt signal (51). This inhibition is potentiated in
the presence of TNF-α (18, 19). However, our findings suggest
that DKK-1 mRNA expression significantly decreased in the pres-
ence of TNF-α, which was associated with osteogenic induction.
This discordance could be related to the use of MSCs, since oppo-
site results have been obtained with synoviocytes (18). Moreover,
serum levels of DKK-1 decreased following anti-TNFα therapy in
RA patients (19) but not in AS patients (52). This suggests that the
effects of TNFα on DKK-1 may not be direct, but may depend on
factors associated with the disease status. Nevertheless, whatever
the effect of TNF-α on DKK-1, we observed a strong correlation
between the decrease of DKK-1 expression and the increase of
bone mineralization. This observation is supported by Kowena
et al. in a review on signaling (51).
Receptor activation of NF-κB ligand, a type II membrane pro-
tein of the TNF superfamily, is expressed in osteoblasts, osteocytes,
and some activated T cells, specifically the Th17 cells (53, 54).
RANKL is implicated in bone homeostasis, with TNFα known to
induce its expression, and IL-17 having a modest effect. Additive
effects of the combination TNFα+ IL-17 on RANKL expres-
sion have been observed in human synoviocytes by us and oth-
ers (55, 56). With hMSCs, opposite results were observed, since
RANKL mRNA expression significantly decreased in the presence
of IL-17A and/or TNF-α, which was associated with osteogenic
induction.
Shn3 expression in mouse MSCs directly controls osteoblastic
bone formation via Runx2, while indirectly regulating osteoclas-
tic bone resorption (32, 33). Shn3-deficient mice show increased
bone mass. However, there is a relative paucity of data on the role of
Shn3 in the human context and its regulation with these cytokines
has not been studied before. Our results showed that TNF-α alone
or combined with IL-17A increased Shn3-mRNA expression levels
at early time. Such increase would be a signal for osteoclast activa-
tion leading to bone destruction. This inter-cellular bridge would
depend on whether osteoclasts are in close proximity with MSCs
or osteoblasts. This difference could explain the different patterns
of bone remodeling observed in RA and AS.
Since IL-17 increased the effects of TNF-α on hMSCs, we exam-
ined the possibility of an effect on TNF-R expression in order
to explain the increased activity often observed with the com-
bination of the two cytokines. TNFRI is ubiquitously expressed
on nearly all cells but TNFRII has a more restricted expression,
specifically on human lymphocytes (57–59) and MSCs (60, 61).
Here, IL-17 and TNF alone or in combination had no effect on
TNFRI expression. In contrast, TNFRII expression was regulated
by the two cytokines in combination, with a modest not signifi-
cant effect when used alone. These results are in line with those
previously observed with synoviocytes, where a regulatory effect
on TNFRII was also observed following exposure to TNF and IL-
17. In this later case, however, IL-17 alone was able to increased
TNFRII expression (62). Our results show that TNF-α and IL-17A
may increase induce osteogenesis via TNFRII overexpression.
Our finding that TNFα and IL-17A activate osteogenesis, with
IL-17A potentiating the effect of TNFα, may explain the mech-
anisms of ligament ossification with ectopic bone formation as
observed in AS. It has been shown that the molecular pathways
underlying AS recapitulate the presence of endochondral bone
formation, where BMPs play a key role (63). Similar to their role
in artery plaque formation during atherosclerosis, type II diabetes,
and aortic valve disease, inflammatory cytokines are strongly sus-
pected to induce ectopic bone formation (64–66). However, the
conditions are different for the local and systemic bone destruc-
tion that is observed in RA. Both in vitro and in vivo results with
TNF inhibitors are in line with the net effect of TNF on bone
loss. Furthermore, the combined inhibition of TNF-α, IL-1, and
IL-17 was more effective than the inhibition of a single cytokine
to control inflammation and bone resorption in an ex vivo RA
model (12).
Application to RA and AS pathogenesis and clinical manifesta-
tions indicates a key difference. In RA, the combination of TNF-α
and IL-17 induces bone loss from massive osteoclast activation
in sites, where osteoblasts and osteoclasts interact locally such as
in juxta-articular sites (12). In contrast, AS is characterized by the
ectopic bone formation from MSC derived from tendons and liga-
ments. At this particular site, osteoclasts are not directly presented
and activated and the combination of TNF-α and IL-17 may then
lead to ectopic ossification (1). Massive bone loss in whole bone
such as vertebra and femoral neck is observed in AS as in RA.
In summary, this is the first study demonstrating that the two
pro-inflammatory cytokines IL-17A and TNF-α can interact to
induce osteogenic differentiation of human MSCs. Through com-
plex interactions, IL-17A can potentiate the effects of TNF-α. An
important new finding in the human context is the effect on
Schunnri3, where the induction by TNF-α is further increased
by IL-17A in a synergistic fashion. Such effect would provide
an activation signal to osteoclasts. A close proximity to osteo-
clasts would be seen in whole bone as in juxta-articular sites
of RA or vertebra in RA and AS. In tendons and ligaments
where osteoclasts are not present, the lack of inter-cellular con-
nection would lead to osteogenesis. At the site of tendon inser-
tion to bone, the destructive pathway would be seen leading to
erosion.
ACKNOWLEDGMENTS
This work has been supported in part by grants from the Region
Rhône-Alpes and the Institut Mérieux. Bilal Osta was supported
by a scholarship from the Region Rhône-Alpes.
REFERENCES
1. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect
(2009) 11:625–30. doi:10.1016/j.micinf.2009.04.003
2. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C,
et al. T cell interleukin-17 induces stromal cells to produce proinflammatory
and hematopoietic cytokines. J Exp Med (1996) 183:2593–603. doi:10.1084/
jem.183.6.2593
Frontiers in Immunology | Inflammation September 2014 | Volume 5 | Article 425 | 6
Osta et al. Effects of IL-17A on osteoblastic formation
3. Koenders MI, Marijnissen RJ, Devesa I, Lubberts E, Joosten LA, Roth J, et al.
Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-
1beta, and matrix metalloproteinases, and drives irreversible cartilage destruc-
tion in murine arthritis: rationale for combination treatment during arthritis.
Arthritis Rheum (2011) 63:2329–39. doi:10.1002/art.30418
4. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17
in synovial fluids from patients with rheumatoid arthritis is a potent stimulator
of osteoclastogenesis. J Clin Invest (1999) 103:1345–52. doi:10.1172/JCI5703
5. Lubberts E, Joosten LA, van de Loo FA, Schwarzenberger P, Kolls J, van den Berg
WB. Overexpression of IL-17 in the knee joint of collagen type II immunized
mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res
(2002) 51:102–4. doi:10.1007/BF02684010
6. Miossec P, Kolls JK. Targeting IL-17 and T(H)17 cells in chronic inflammation.
Nat Rev Drug Discov (2012) 11:763–76. doi:10.1038/nrd3794
7. Baeten D, Sieper J, Emery P, Braun J, van der Heijde D, McInnes I, et al. The
anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety
and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum
(2010) 62:3840. Abstract L7.
8. Koenders MI, Kolls JK, Oppers-Walgreen B, van den Bersselaar L, Joosten LA,
Schurr JR, et al. Interleukin-17 receptor deficiency results in impaired synovial
expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and pre-
vents cartilage destruction during chronic reactivated streptococcal cell wall-
induced arthritis. Arthritis Rheum (2005) 52:3239–47. doi:10.1002/art.21342
9. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM,
Di Padova FE, et al. Blocking of interleukin-17 during reactivation of experi-
mental arthritis prevents joint inflammation and bone erosion by decreasing
RANKL and interleukin-1. Am J Pathol (2005) 167:141–9. doi:10.1016/S0002-
9440(10)62961-6
10. Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, et al. Analy-
sis of IL-17(+) cells in facet joints of patients with spondyloarthritis sug-
gests that the innate immune pathway might be of greater relevance than the
Th17-mediated adaptive immune response. Arthritis Res Ther (2011) 13:R95.
doi:10.1186/ar3370
11. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, et al.
LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treat-
ment of patients with rheumatoid arthritis: a phase I randomized, double-blind,
placebo-controlled, proof-of-concept study. Arthritis Rheum (2010) 62:929–39.
doi:10.1002/art.27334
12. Chabaud M, Miossec P. The combination of tumor necrosis factor alpha block-
ade with interleukin-1 and interleukin-17 blockade is more effective for control-
ling synovial inflammation and bone resorption in an ex vivo model. Arthritis
Rheum (2001) 44:1293–303. doi:10.1002/1529-0131(200106)44:6<1293::AID-
ART221>3.0.CO;2-T
13. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al.
Th17 functions as an osteoclastogenic helper T cell subset that links T cell acti-
vation and bone destruction. J Exp Med (2006) 203:2673–82. doi:10.1084/jem.
20061775
14. Li X, Yuan FL, Lu WG, Zhao YQ, Li CW, Li JP, et al. The role of interleukin-
17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res
Commun (2010) 397:131–5. doi:10.1016/j.bbrc.2010.05.111
15. Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-
alpha on macrophage inflammatory protein-3alpha production in rheumatoid
arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol (2001)
167:6015–20. doi:10.4049/jimmunol.167.10.6015
16. Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, et al. IL-17 induces
production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via
NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther (2004)
6:R120–8. doi:10.1186/ar1038
17. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD. Interleukin
17 induces cartilage collagen breakdown: novel synergistic effects in combi-
nation with proinflammatory cytokines. Ann Rheum Dis (2002) 61:704–13.
doi:10.1136/ard.61.8.704
18. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-
1 is a master regulator of joint remodeling. Nat Med (2007) 13:156–63.
doi:10.1038/nm1538
19. Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X, et al. Circulating Dickkopf-1 is corre-
lated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol
(2011) 38:821–7. doi:10.3899/jrheum.100089
20. Guo R, Yamashita M, Zhang Q, Zhou Q, Chen D, Reynolds DG, et al. Ubiquitin
ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by
promoting proteasomal degradation of bone morphogenetic signaling proteins.
J Biol Chem (2008) 283:23084–92. doi:10.1074/jbc.M709848200
21. Kaneki H, Guo R, Chen D, Yao Z, Schwarz EM, Zhang YE, et al. Tumor
necrosis factor promotes Runx2 degradation through up-regulation of Smurf1
and Smurf2 in osteoblasts. J Biol Chem (2006) 281:4326–33. doi:10.1074/jbc.
M509430200
22. Krum SA, Chang J, Miranda-Carboni G, Wang CY. Novel functions for NFkap-
paB: inhibition of bone formation. Nat Rev Rheumatol (2010) 6:607–11.
doi:10.1038/nrrheum.2010.133
23. Noh M. Interleukin-17A increases leptin production in human bone marrow
mesenchymal stem cells. Biochem Pharmacol (2012) 83:661–70. doi:10.1016/j.
bcp.2011.12.010
24. Huang H, Zhao N, Xu X, Xu Y, Li S, Zhang J, et al. Dose-specific effects of tumor
necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells.
Cell Prolif (2011) 44:420–7. doi:10.1111/j.1365-2184.2011.00769.x
25. Hess K, Ushmorov A, Fiedler J, Brenner RE, Wirth T. TNFalpha promotes
osteogenic differentiation of human mesenchymal stem cells by trigger-
ing the NF-kappaB signaling pathway. Bone (2009) 45:367–76. doi:10.1016/j.
bone.2009.04.252
26. Mountziaris PM, Tzouanas SN, Mikos AG. Dose effect of tumor necrosis factor-
alpha on in vitro osteogenic differentiation of mesenchymal stem cells on
biodegradable polymeric microfiber scaffolds. Biomaterials (2010) 31:1666–75.
doi:10.1016/j.biomaterials.2009.11.058
27. Yu RY, Zeng BJ, Liu YS, Zhou YS. Recombinant human tumor necrosis
factor-alpha promotes human adipose-derived stromal cells transforming into
osteoblast in vitro. Beijing Da Xue Xue Bao (2012) 44:475–80.
28. Lu Z, Wang G, Dunstan CR, Zreiqat H. Short-term exposure to tumor necrosis
factor-alpha enables human osteoblasts to direct adipose tissue-derived mes-
enchymal stem cells into osteogenic differentiation. Stem Cells Dev (2012)
21:2420–9. doi:10.1089/scd.2011.0589
29. Glass GE, Chan JK, Freidin A, Feldmann M, Horwood NJ, Nanchahal J. TNF-
alpha promotes fracture repair by augmenting the recruitment and differ-
entiation of muscle-derived stromal cells. Proc Natl Acad Sci U S A (2011)
108:1585–90. doi:10.1073/pnas.1018501108
30. Osta B, Benedetti G, Miossec P. Classical and paradoxical effects of TNF-
alpha on bone homeostasis. Front Immunol (2014) 5:48. doi:10.3389/fimmu.
2014.00048
31. Huang H, Kim HJ, Chang EJ, Lee ZH, Hwang SJ, Kim HM, et al. IL-17
stimulates the proliferation and differentiation of human mesenchymal stem
cells: implications for bone remodeling. Cell Death Differ (2009) 16:1332–43.
doi:10.1038/cdd.2009.74
32. Wein MN, Jones DC, Shim JH, Aliprantis AO, Sulyanto R, Lazarevic V, et al.
Control of bone resorption in mice by Schnurri-3. Proc Natl Acad Sci U S A
(2012) 109:8173–8. doi:10.1073/pnas.1205848109
33. Jones DC, Wein MN, Oukka M, Hofstaetter JG, Glimcher MJ, Glimcher LH.
Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3.
Science (2006) 312:1223–7. doi:10.1126/science.1126313
34. Jones DC, Wein MN, Glimcher LH. Schnurri-3 is an essential regulator of
osteoblast function and adult bone mass. Ann Rheum Dis (2007) 66(Suppl
3):iii49–51. doi:10.1136/ard.2007.078352
35. Kamiya N, Mishina Y. New insights on the roles of BMP signaling in bone-A
review of recent mouse genetic studies. Biofactors (2011) 37:75–82. doi:10.1002/
biof.139
36. Jones DC, Wein MN, Glimcher LH. Schnurri-3: a key regulator of postnatal
skeletal remodeling. Adv Exp Med Biol (2007) 602:1–13. doi:10.1007/978-0-
387-72009-8_1
37. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcrip-
tional activator of osteoblast differentiation. Cell (1997) 89:747–54. doi:10.1016/
S0092-8674(00)80257-3
38. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modu-
lation of osteoclast differentiation and function by the new members of the
tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 20:345–57.
doi:10.1210/edrv.20.3.0367
39. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, et al. Dkk1-
mediated inhibition of Wnt signaling in bone results in osteopenia. Bone (2006)
39:754–66. doi:10.1016/j.bone.2006.03.017
www.frontiersin.org September 2014 | Volume 5 | Article 425 | 7
Osta et al. Effects of IL-17A on osteoblastic formation
40. Faustman DL, Davis M. TNF receptor 2 and disease: autoimmunity and regen-
erative medicine. Front Immunol (2013) 4:478. doi:10.3389/fimmu.2013.00478
41. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune
diseases. Nat Rev Drug Discov (2010) 9:482–93. doi:10.1038/nrd3030
42. Mojsilovic S, Krstic A, Ilic V, Okic-Dordevic I, Kocic J, Trivanovic D, et al. IL-17
and FGF signaling involved in mouse mesenchymal stem cell proliferation. Cell
Tissue Res (2011) 346:305–16. doi:10.1007/s00441-011-1284-5
43. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain
kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity (1998)
8:297–303. doi:10.1016/S1074-7613(00)80535-X
44. Granet C, Miossec P. Combination of the pro-inflammatory cytokines IL-1,
TNF-alpha and IL-17 leads to enhanced expression and additional recruitment
of AP-1 family members, Egr-1 and NF-kappaB in osteoblast-like cells. Cytokine
(2004) 26:169–77. doi:10.1016/j.cyto.2004.03.002
45. Zhao L, Huang J, Zhang H, Wang Y, Matesic LE, Takahata M, et al. Tumor necro-
sis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the
ubiquitin E3 ligase Wwp1. Stem Cells (2011) 29:1601–10. doi:10.1002/stem.703
46. Kehlen A, Thiele K, Riemann D, Langner J. Expression, modulation and sig-
nalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheuma-
toid arthritis. Clin Exp Immunol (2002) 127:539–46. doi:10.1046/j.1365-2249.
2002.01782.x
47. Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in
articular chondrocytes is associated with activation of mitogen-activated pro-
tein kinases and NF-kappaB. J Biol Chem (1998) 273:27467–73. doi:10.1074/jbc.
273.42.27467
48. Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, Ungvari Z. Regula-
tion of bone morphogenetic protein-2 expression in endothelial cells: role of
nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and
high intravascular pressure. Circulation (2005) 111:2364–72. doi:10.1161/01.
CIR.0000164201.40634.1D
49. Fukui N, Zhu Y, Maloney WJ, Clohisy J, Sandell LJ. Stimulation of BMP-
2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal
and osteoarthritic chondrocytes. J Bone Joint Surg Am (2003) 85-A(Suppl
3):59–66.
50. Okabe T, Matsushima K. Regulation of ALP activity by TNF-alpha on human
dental pulp. J Endod (2006) 32:516–20. doi:10.1016/j.joen.2005.12.007
51. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell
Sci (2003) 116:2627–34. doi:10.1242/jcs.00623
52. Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, et al. Dickkopf-1 level
is lower in patients with ankylosing spondylitis than in healthy people and is
not influenced by anti-tumor necrosis factor therapy. Rheumatol Int (2012)
32:2523–7. doi:10.1007/s00296-011-1981-0
53. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells
regulate bone loss and joint destruction in adjuvant arthritis through osteopro-
tegerin ligand. Nature (1999) 402:304–9. doi:10.1038/46303
54. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, et al. Evi-
dence for osteocyte regulation of bone homeostasis through RANKL expression.
Nat Med (2011) 17:1231–4. doi:10.1038/nm.2452
55. Page G, Miossec P. RANK and RANKL expression as markers of dendritic cell-T
cell interactions in paired samples of rheumatoid synovium and lymph nodes.
Arthritis Rheum (2005) 52:2307–12. doi:10.1002/art.21211
56. Tunyogi-Csapo M, Kis-Toth K, Radacs M, Farkas B, Jacobs JJ, Finnegan
A, et al. Cytokine-controlled RANKL and osteoprotegerin expression by human
and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
Arthritis Rheum (2008) 58:2397–408. doi:10.1002/art.23653
57. Ware CF, Crowe PD, Vanarsdale TL, Andrews JL, Grayson MH, Jerzy R, et al.
Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential
regulation of the type I TNF receptor during activation of resting and effector
T cells. J Immunol (1991) 147:4229–38.
58. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alpha
promotes proliferation of oligodendrocyte progenitors and remyelination. Nat
Neurosci (2001) 4:1116–22. doi:10.1038/nn738
59. Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, et al. Tissue expres-
sion and immunolocalization of tumor necrosis factor-alpha in postinfarction
dysfunctional myocardium. Circulation (1999) 99:1492–8. doi:10.1161/01.CIR.
99.11.1492
60. Bocker W, Docheva D, Prall WC, Egea V, Pappou E, Rossmann O, et al. IKK-2
is required for TNF-alpha-induced invasion and proliferation of human mes-
enchymal stem cells. J Mol Med (Berl) (2008) 86:1183–92. doi:10.1007/s00109-
008-0378-3
61. Pimentel-Muinos FX, Seed B. Regulated commitment of TNF receptor signal-
ing: a molecular switch for death or activation. Immunity (1999) 11:783–93.
doi:10.1016/S1074-7613(00)80152-1
62. Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis MA, Miossec P. Genome-
wide comparison between IL-17A- and IL-17F-induced effects in human
rheumatoid arthritis synoviocytes. J Immunol (2009) 182:3112–20. doi:10.4049/
jimmunol.0801967
63. Carter S, Braem K, Lories RJ. The role of bone morphogenetic proteins in
ankylosing spondylitis. Ther Adv Musculoskelet Dis (2012) 4:293–9. doi:10.1177/
1759720X12444175
64. Demer LL. Vascular calcification and osteoporosis: inflammatory responses to
oxidized lipids. Int J Epidemiol (2002) 31:737–41. doi:10.1093/ije/31.4.737
65. Doherty TM, Asotra K, Fitzpatrick LA, Qiao JH, Wilkin DJ, Detrano RC,
et al. Calcification in atherosclerosis: bone biology and chronic inflamma-
tion at the arterial crossroads. Proc Natl Acad Sci U S A (2003) 100:11201–6.
doi:10.1073/pnas.1932554100
66. Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic valve stenosis: an active
atheroinflammatory process. Curr Opin Lipidol (2007) 18:483–91. doi:10.1097/
MOL.0b013e3282a66099
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 17 June 2014; accepted: 19 August 2014; published online: 02 September 2014.
Citation: Osta B, Lavocat F, Eljaafari A and Miossec P (2014) Effects of interleukin-
17A on osteogenic differentiation of isolated human mesenchymal stem cells. Front.
Immunol. 5:425. doi: 10.3389/fimmu.2014.00425
This article was submitted to Inflammation, a section of the journal Frontiers in
Immunology.
Copyright © 2014 Osta, Lavocat , Eljaafari and Miossec. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Immunology | Inflammation September 2014 | Volume 5 | Article 425 | 8
